Alan E. Wakeling - Concepedia

Author

Alan E. Wakeling

AstraZeneca (United Kingdom)

Also Known As

A E Wakeling, ALAN E. WAKELING, Alan E. Wakeling, Alan Wakeling, BindingDB

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Tenovus Cancer Care Cardiff University University of Wales University of Manchester

About

Alan E. Wakeling is an author at AstraZeneca (United Kingdom) specializing in medicine, breast cancer, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	19	1.8K
2	Cell Biology	10	10	1.1K
3	Public Health	2	2	101
4	Biochemistry	2	2	120
5	Diabetes	1	1	207

Alan E. Wakeling

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells Janice M. Knowlden, Iain R. Hutcheson, Helen E. Jones, Endocrinology	2003	525
Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor Andrew Gilmore, Anthony Valentijn, Pengbo Wang, Journal of Biological Chemistry ApoptosisCell DeathDermatologyCell GrowthCancer Biology	2002	207
Novel steroidal pure antiestrogens Jean Bowler, Timothy J. Lilley, John D. Pittam, Steroids Medicinal ChemistryMedicineHormonal ReceptorPharmacotherapyEndocrinology	1989	206
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi, PubMed PathologyCell ProliferationDermatologyTumor BiologyOncology	2004	182
Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells Iain R. Hutcheson, Janice M. Knowlden, Tracie‐Ann Madden, Breast Cancer Research and Treatment Cancer ResearchBreast OncologyHormonal ReceptorBreast CancerTamoxifen-resistant Mcf-7 Cells	2003	172
Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor–Positive, HER-2/<i>neu</i>-Positive Breast Cancer Suleiman Massarweh, C. Kent Osborne, Shou Jiang, Cancer Research	2006	149
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth C. Kent Osborne, Michael Jarman, R. MCCAGUE, Cancer Chemotherapy and Pharmacology Tamoxifen MetabolismBreast OncologyOncologyMedicineCancer Growth	1994	132
Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells Nicola Jordan, Julia M.W. Gee, Denise Barrow, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyMedicinePharmacologyCancer Growth	2004	125
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839) Stephen Hiscox, L. Morgan, Denise Barrow, Clinical & Experimental Metastasis Breast OncologyTamoxifen ResistanceMedicineBreast Cancer CellsPharmacology	2004	111
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Nils Brünner, Thomas Leth Frandsen, Claus Holst‐Hansen, PubMed Tumor BiologyEndocrine OncologyBreast OncologyAntiestrogen TamoxifenMedicine	1993	105

Page 1